We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
-31.86%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$304M
AUM Growth
-$149M
Cap. Flow
+$1.66M
Cap. Flow %
0.55%
Top 10 Hldgs %
84.19%
Holding
25
New
1
Increased
8
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$16.3M
2
AERI
Aerie Pharmaceuticals
AERI
+$11.4M
3
FBRX icon
Forte Biosciences
FBRX
+$5.93M
4
NTRA icon
Natera
NTRA
+$4.61M
5
AKAO
Achaogen Inc
AKAO
+$1.31M

Top Sells

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$16.5M
2
PACB icon
Pacific Biosciences
PACB
+$6.14M
3
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$4.5M
4
SLDB icon
Solid Biosciences
SLDB
+$4.35M
5
VRNA
Verona Pharma
VRNA
+$3.34M

Sector Composition

Rank Sector Weight
1 Healthcare 57.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
1
DELISTED
Aerie Pharmaceuticals
AERI
$70.4M 23.13%
1,950,477
+242,431
+14% +$11.4M
IMMU
2
DELISTED
Immunomedics Inc
IMMU
$38.5M 12.65%
2,700,000
+8,271
+0.3% +$164K
ALDR
3
DELISTED
Alder Biopharmaceuticals
ALDR
$30.2M 9.9%
2,942,130
– –
BPMC
4
DELISTED
Blueprint Medicines
BPMC
$25.2M 8.28%
467,682
+267,682
+134% +$16.3M
RCUS icon
5
Arcus Biosciences
RCUS
$3.38B
$21.9M 7.18%
2,028,876
-1,416,585
-41% -$16.5M
MYOK
6
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$17.7M 5.8%
361,441
-10,859
-3% -$598K
AIMT
7
DELISTED
Aimmune Therapeutics
AIMT
$17M 5.58%
709,822
-91,418
-11% -$2.37M
ASND icon
8
Ascendis Pharma A/S
ASND
$16.4B
$12.8M 4.2%
204,088
+12,500
+7% +$785K
CBAY
9
DELISTED
Cymabay Therapeutics
CBAY
$12.5M 4.1%
1,587,101
+25,061
+2% +$239K
XLRN
10
DELISTED
Acceleron Pharma
XLRN
$10.3M 3.37%
235,868
-14,995
-6% -$749K
REPL icon
11
Replimune Group
REPL
$443M
$7.8M 2.56%
779,656
– –
BOLD
12
DELISTED
Audentes Therapeutics, Inc
BOLD
$6.72M 2.21%
315,331
– –
EPZM
13
DELISTED
Epizyme, Inc
EPZM
$6.15M 2.02%
998,215
+80,500
+9% +$615K
FBRX icon
14
Forte Biosciences
FBRX
$1.57B
$5.46M 1.79%
1,774
+1,378
+348% +$5.93M
BHVN
15
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$3.91M 1.28%
105,706
– –
AKAO
16
DELISTED
Achaogen Inc
AKAO
$3.52M 1.16%
2,864,664
+490,246
+21% +$1.31M
NTRA icon
17
Natera
NTRA
$36.4B
$3.52M 1.16%
+252,255
New +$4.61M
SLDB icon
18
Solid Biosciences
SLDB
$775M
$2.65M 0.87%
6,596
-9,263
-58% -$4.35M
BDSI
19
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$2.33M 0.77%
629,656
– –
WVE icon
20
Wave Life Sciences
WVE
$1.14B
$2.1M 0.69%
50,000
– –
VRNA
21
DELISTED
Verona Pharma
VRNA
$1.99M 0.65%
206,663
-294,220
-59% -$3.34M
ACRS icon
22
Aclaris Therapeutics
ACRS
$739M
$1.96M 0.64%
265,694
-46,674
-15% -$481K
ARDX icon
23
Ardelyx
ARDX
$1.25B
– –
-130,304
Closed -$567K
PACB icon
24
Pacific Biosciences
PACB
$435M
– –
-1,135,000
Closed -$6.14M
SGMO
25
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-265,605
Closed -$4.5M

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q4 2018 Portfolio in Review

As of Q4 2018, Foresite Capital Management III held 25 positions worth $304M, down 33% from $453M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Foresite Capital Management III's Q4 2018 filing shows 1 new, 8 increased, 7 reduced and 3 closed positions. Its largest new stake was Natera: 252,255 shares worth $3.52M. The largest sale was Arcus Biosciences, an estimated $16.5M.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 58% a quarter earlier.

  • Foresite Capital Management III's largest Q4 2018 buy was Natera: 252,255 shares worth $3.52M.
  • Foresite Capital Management III added most to Blueprint Medicines in Q4 2018, an estimated $16.3M increase.
  • Foresite Capital Management III's biggest Q4 2018 reduction was Arcus Biosciences, cutting an estimated $16.5M.
  • Foresite Capital Management III fully exited Pacific Biosciences in Q4 2018, selling an estimated $6.14M.
  • Foresite Capital Management III's ten largest holdings make up 84% of its $304M portfolio in Q4 2018.
  • Foresite Capital Management III opened 1 new position and closed 3 in Q4 2018.
  • Foresite Capital Management III's portfolio value fell 33% quarter-over-quarter to $304M.

Based on Foresite Capital Management III's 13F filing for Q4 2018, filed 13 Feb 2019.